

Dermapharm Holding SE



WKN: A2GS5D ISIN: DE000A2GS5D8 Land: Deutschland

Nachricht vom 04.03.2019 | 17:51

## Dermapharm Holding SE acquires a stake in cannabis producer for pharmaceutical applications

Dermapharm Holding SE / Key word(s): Investment

Dermapharm Holding SE acquires a stake in cannabis producer for pharmaceutical applications

04-March-2019 / 17:51 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

### Disclosure of insider information pursuant to Section 17 (1) 1 of the EU Regulation no. 596/2014 on market abuse as amended (Market Abuse Regulation - MAR)

#### *Dermapharm Holding SE acquires a stake in cannabis producer for pharmaceutical applications*

Grünwald, March 4, 2019 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) concluded an agreement today to acquire a stake in the companies FYTA Company B.V. and FYTA Tech B.V., both headquartered in Waalwijk, Netherlands, as well as FYTA Company GmbH and FYTA Vermögensverwaltung GmbH, both headquartered in Monheim, Germany. By signing the contract, Dermapharm Holding SE is acquiring 20.00 percent of the shares in the companies specializing in the production of medical cannabis for pharmaceutical applications with effect from March 4, 2019. The parties have agreed not to disclose the purchase price. The approval required for medical cannabis production was granted by the Dutch regulatory authority (CIBG)<sup>(1)</sup> on February 25, 2019. The approval covers around 12 tons of medical cannabis per year and is expandable. FYTA currently has its own state-of-the-art indoor production facility in Waalwijk that enables the production of up to 25 tons of medical cannabis per year. The transaction also includes the assignment of 49.9% of the shares in the 100% axicorp subsidiary Remedix GmbH, based in Friedrichsdorf, Germany, to UWF Beteiligungsgesellschaft mbH, based in Monheim, Germany. As a re-importer in the pharmaceutical sector, Remedix GmbH is specialized in EU narcotics and licensed by the Federal Opium Agency to trade in narcotics. Remedix GmbH will take over the import to Germany and distribution of medical cannabis as a joint platform between Dermapharm and the FYTA companies.

1) Ministerie von Volksgezondheid, Welzijn en Sport

&gt;End of ad hoc announcement&lt;

#### Contacts

Investor Relations  
 Britta Hamberger  
 Phone: +49 (0)89 - 64186-233  
 Fax: +49 (0)89 - 64186-165  
 email: ir@dermapharm.com

cometis AG  
 Claudius Krause  
 Phone: +49 (0)611 - 205855-28  
 Fax: +49 (0)611 - 205855-66  
 email: ir@dermapharm.com

04-March-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.  
 Archive at [www.dgap.de](http://www.dgap.de)

Language: English  
 Company: Dermapharm Holding SE  
 Lil-Dagover-Ring 7  
 82031 Grünwald  
 Germany  
 Phone: +49 (0)89 64 86-0  
 E-mail: [ir@dermapharm.de](mailto:ir@dermapharm.de)

Internet: [ir.dermapharm.de](http://ir.dermapharm.de)

ISIN: DE000A2GS5D8

WKN: A2GS5D

Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange

End of Announcement

DGAP News Service

 show this

DGAP – ein Service der EQS Group AG

[Twitter](#) | [Impressum](#) | [AGB](#) | [Datenschutzhinweise](#) | [Cookie-Richtlinie](#)